By doing so, one can incorporate IDC-P, a significant adverse pathological parameter, in the risk stratification tools to avoid undergrading and undertreating biologically aggressive PCa, ensure correct prognostication, and obviate the excessive use of BCM IHC (see discussion below). The gene discussed is TNFRSF17; the disease is posterior cortical atrophy.